Metrics to compare | 328130 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship328130PeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.6x | −3.2x | −0.2x | |
PEG Ratio | −0.66 | 0.05 | 0.00 | |
Price / Book | 3.3x | 1.1x | 2.6x | |
Price / LTM Sales | 11.9x | 3.9x | 2.8x | |
Upside (Analyst Target) | −30.8% | 84.0% | 62.7% | |
Fair Value Upside | Unlock | 36.7% | 8.0% | Unlock |
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research; and with Summit Therapeutics Inc. to apply AI-powered SCOPE IO pathology platform for tumor microenvironment analysis in immuno-oncology development. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.